Delix Therapeutics
PrivateLast Round
Series C
Aug 18, 2026
Est. Valuation
$275M
Total Funding Raised
$126.2M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Delix Therapeutics is a biotechnology company that develops novel, non-hallucinogenic psychoplastogen therapeutics to treat severe psychiatric and neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Delix Therapeutics Comparables
Compare Delix Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lophora | 86% | |
| Gilgamesh Pharmaceuticals | 85% | |
| Xylo Bio | 83% |
Delix Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 18, 2026 | ||||
| Strategic | Sep 10, 2025 | ||||
| Grant | Jun 4, 2024 | ||||
| Grant | Dec 13, 2023 | ||||
| Convertible Debt | Jan 10, 2022 | ||||
Debt | Jan 10, 2022 |
Key People
Founding team and executive leadership
Delix Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Casa Verde Capital | Series A |
| National Institute on Drug Abuse | Grant |
| RA Capital Management | Series A |
| Dolby Family Ventures | Series A |
| United States Department of Defense | Grant |
| U.S. Department of Defense | Grant |
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 18, 2026
Raised $85M led by Johnson & Johnson
- Jun 4, 2024
$825K grant from U.S. Department of War and Department of Defense.
Delix Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Delix Therapeutics's valuation, stock price, and market status.
Is Delix Therapeutics a public or private company?
Delix Therapeutics is a private company.
What is the current stock price of Delix Therapeutics?
Delix Therapeutics is a private company, so its shares have no public market price. Caplight tracks Delix Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Delix Therapeutics worth (valuation)?
Delix Therapeutics's valuation is estimated at $275.0M based on funding round data.
Can I buy Delix Therapeutics stock?
Delix Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Delix Therapeutics's last funding round?
Delix Therapeutics's most recent funding round was Series C on August 18, 2026.
Who are the main investors in Delix Therapeutics?
Key investors in Delix Therapeutics include National Institute on Drug Abuse, RA Capital Management, United States Department of Defense, OMX Ventures, ARTIS Ventures.
Will Delix Therapeutics IPO soon?
No public IPO plans have been announced for Delix Therapeutics.
How can I track Delix Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Delix Therapeutics's shares on secondary markets.